(21.4.2010, LISBON) Harm reduction is now an integral part of contemporary drug policies and plays an important role in responding to drug use in Europe. But this has not always been the case, say the experts. In a major new scientific work on the subject published today by the EU drugs agency (EMCDDA), leading European and international specialists chart how harm reduction shifted from controversy to mainstream.
In this latest EMCDDA monograph — Harm reduction: evidence, impacts and challenges — over 50 authors examine two decades of harm reduction research and practice in Europe and beyond (1). They also wrestle with how the concept may broaden and evolve as patterns of drug use change.
|Source:||European Monitoring Centre for Drugs and Drug Addiction|
|Date:||23 April 2010|
|Corporate Creators:||European Monitoring Centre for Drugs and Drug Addiction|
|Subjects:||J Health care, prevention and rehabilitation > Drugs and alcohol prevention > Drugs and alcohol use harm reduction|
MP-MR Policy, planning, economics, work and social services > Policy > Policy on drugs and alcohol > Harm reduction policy
Repository Staff Only: item control page